Pulse Biosciences (NASDAQ:PLSE) posted its quarterly earnings data on Thursday. The company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.04), Bloomberg Earnings reports.
Pulse Biosciences stock traded down $0.78 during midday trading on Friday, reaching $10.75. The stock had a trading volume of 93,609 shares, compared to its average volume of 39,703. The company has a debt-to-equity ratio of 0.02, a quick ratio of 17.13 and a current ratio of 17.13. Pulse Biosciences has a 52-week low of $8.60 and a 52-week high of $19.77. The company has a market capitalization of $238.79 million, a price-to-earnings ratio of -4.89 and a beta of 1.79. The stock has a fifty day simple moving average of $12.59.
A number of research firms recently weighed in on PLSE. ValuEngine raised shares of Pulse Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. HC Wainwright reissued a “buy” rating on shares of Pulse Biosciences in a research report on Wednesday, May 1st. Finally, BidaskClub lowered shares of Pulse Biosciences from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 16th.
Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.
Recommended Story: Risk Tolerance
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.